Johnson & Johnson flags Cypher stent as important growth driver
This article was originally published in Clinica
Executive Summary
Johnson & Johnson has reported 18.5% growth in its device and diagnostics business, with full-year sales coming in at $14.9bn. It said its Cordis business was a "key contributor" to the results, with the Cypher sirolimus-eluting coronary stent, which was launched in the US during the year, representing the "primary driver".